drugset / Trial / NCT07537257
VEN+IDAC vs IDAC in AML
Phase 2/3
Enrolling by invitation
232 enrolled
Guangdong Second Provincial General Hospital
Dongguan People's Hospital · collabFirst Affiliated Hospital of Guangxi Medical University · collabGuangzhou First People's Hospital · collabNanfang Hospital, Southern Medical University · collabShenzhen Second People's Hospital · collabShunde Hospital, Sothen Medical University · collabSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · collabZhongshan People's Hospital, Guangdong, China · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study intends to use a randomized controlled design to compare the MRD-negativw rate and related efficacy and safety of venetoclax combined with intermediate-dose cytarabine (IDAC) versus IDAC in the consolidation treatment of patients with AML after remission, providing high-quality evidence-based medical evidence for optimizing post-remission consolidation therapy for AML and improving patients' prognosis.
Timeline
- Start
- 2026-04-01
- Primary completion
- 2027-04-01
- Completion
- 2029-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Venetoclax | Small molecule | 400 mg | — |
| Background | Cytarabine | Small molecule | 1.5 g | — |